OXFORD, UK – April 28, 2014
Orca Pharmaceuticals, a biotechnology start-up developing RORgamma inhibitors for the treatment of autoimmune diseases, has announced a further investment of $1.3 million from BioMotiv, a drug development accelerator based in Cleveland, Ohio and affiliated with The Harrington Project.